PT3283064T - Derivados úteis para o tratamento da atrofia muscular - Google Patents

Derivados úteis para o tratamento da atrofia muscular

Info

Publication number
PT3283064T
PT3283064T PT16729310T PT16729310T PT3283064T PT 3283064 T PT3283064 T PT 3283064T PT 16729310 T PT16729310 T PT 16729310T PT 16729310 T PT16729310 T PT 16729310T PT 3283064 T PT3283064 T PT 3283064T
Authority
PT
Portugal
Prior art keywords
treatment
muscle atrophy
derivatives used
derivatives
atrophy
Prior art date
Application number
PT16729310T
Other languages
English (en)
Inventor
Lepifre Franck
Durand Jean-Denis
Autier Valérie
G Charon Christine
N Raynal Sophie
M Audet Annick
R Kergoat Micheline
Original Assignee
Metabrain Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabrain Res filed Critical Metabrain Res
Publication of PT3283064T publication Critical patent/PT3283064T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PT16729310T 2015-04-16 2016-04-14 Derivados úteis para o tratamento da atrofia muscular PT3283064T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1553410A FR3035105A1 (fr) 2015-04-16 2015-04-16 Derives utiles dans le traitement de l'atrophie musculaire

Publications (1)

Publication Number Publication Date
PT3283064T true PT3283064T (pt) 2019-08-21

Family

ID=53758355

Family Applications (1)

Application Number Title Priority Date Filing Date
PT16729310T PT3283064T (pt) 2015-04-16 2016-04-14 Derivados úteis para o tratamento da atrofia muscular

Country Status (13)

Country Link
US (1) US10350184B2 (pt)
EP (1) EP3283064B1 (pt)
JP (1) JP6669774B2 (pt)
KR (1) KR20170137201A (pt)
CN (1) CN107735082B (pt)
CA (1) CA2988625A1 (pt)
DK (1) DK3283064T3 (pt)
ES (1) ES2741012T3 (pt)
FR (1) FR3035105A1 (pt)
PL (1) PL3283064T3 (pt)
PT (1) PT3283064T (pt)
RU (1) RU2715553C2 (pt)
WO (1) WO2016166480A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3055548B1 (fr) * 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
CN111253246B (zh) * 2020-03-16 2023-03-17 中国医学科学院基础医学研究所 酰基酸类衍生物及其制备方法和医药用途
CN114533731A (zh) * 2022-02-25 2022-05-27 上海大学 一种氨基吡啶衍生物在制备肌肉萎缩抑制剂中的应用
CN117205215B (zh) * 2023-11-08 2024-01-26 广州喜鹊医药有限公司 川芎嗪硝酮衍生物在制备预防或治疗肌少症药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204406A1 (en) * 1972-10-26 1974-05-24 Delalande Sa 1-Phenyl-3-aminocarbonylpropan-1-one oxime carbamates - with analgesic, antiinflammatory, hypotensive and sedative activities etc.
AU4159197A (en) * 1996-09-04 1998-03-26 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6541521B1 (en) * 1999-07-12 2003-04-01 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
WO2001070674A1 (en) * 2000-03-20 2001-09-27 N-Gene Research Laboratories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
HUE032640T2 (en) * 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2017044551A1 (en) * 2015-09-11 2017-03-16 Mitobridge, Inc. Ppar-alpha agonists for treating mitochondrial diseases

Also Published As

Publication number Publication date
RU2715553C2 (ru) 2020-03-02
RU2017139915A (ru) 2019-05-17
CA2988625A1 (en) 2016-10-20
WO2016166480A1 (fr) 2016-10-20
KR20170137201A (ko) 2017-12-12
CN107735082A (zh) 2018-02-23
US10350184B2 (en) 2019-07-16
DK3283064T3 (da) 2019-08-12
FR3035105A1 (fr) 2016-10-21
PL3283064T3 (pl) 2019-12-31
EP3283064A1 (fr) 2018-02-21
CN107735082B (zh) 2021-07-27
JP2018513162A (ja) 2018-05-24
EP3283064B1 (fr) 2019-05-08
JP6669774B2 (ja) 2020-03-25
ES2741012T3 (es) 2020-02-07
US20180303780A1 (en) 2018-10-25
RU2017139915A3 (pt) 2019-06-06

Similar Documents

Publication Publication Date Title
HK1254525A1 (zh) 治療組合物、組合和使用方法
HK1256283A1 (zh) 治療癌症有用的二氫咪唑並吡嗪酮衍生物
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
SG11201707085VA (en) Treatment of wood
HK1245658A1 (zh) 可用於治療ibd患者的營養組合物
GB201511382D0 (en) Novel compounds and their use in therapy
PT3283064T (pt) Derivados úteis para o tratamento da atrofia muscular
PT3135110T (pt) Derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processos para a produção e utilização dos mesmos
HK1258502A1 (zh) 用於治療高胱氨酸尿症的組合物和方法
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
EP3341006A4 (en) COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
ZA201802201B (en) Novel formulation and treatment methods
PT3548006T (pt) Composição para utilização no tratamento de alterações intestinais
SG11201706369PA (en) Compositions and methods for the treatment of mucositis
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB201511772D0 (en) Improvements in the treatment of ash
GB201521083D0 (en) Compositions for treatment and methods thereof
AU2015904350A0 (en) Composition and methods for the prevention and treatment of muscle atrophy
GB201502816D0 (en) Novel Compositions having use in therapy
GB201419559D0 (en) Therapeutic compositions and methods